

University of Groningen

Pharmacoeconomics of cardiovascular disease prevention

Stevanovic, Jelena

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Stevanovic, J. (2015). *Pharmacoeconomics of cardiovascular disease prevention*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

List of publications

Peer reviewed international publications supporting this thesis

Stevanovic J, Postma MJ, Pechlivanoglou P. A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention. *European Journal of Preventive Cardiology*. 2012 Aug;19(2 Suppl):42-53.

Stevanović J, O'Prinsen AC, Verheggen BG, Schuiling-Veninga N, Postma MJ, Pechlivanoglou P. Economic Evaluation of Primary Prevention of Cardiovascular Diseases in Mild Hypertension: A Scenario Analysis for the Netherlands. *Clinical Therapeutics* 2014;36(3):368-384.

Stevanović J, Pompen M, Le HH, Rozenbaum MH, Tieleman RG, Postma MJ. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. *Plos one*, 2014.

van Leent MWJ, Stevanović J, Jansman FG, Beinema MJ, Brouwers JRBJ, Postma MJ. Cost-effectiveness of dabigatran compared to vitamin-K antagonists for the treatment of deep venous thrombosis in the Netherlands using real-world data. *Plos one*, 2015.

Stevanović J, Pechlivanoglou P, Kampinga MA, Krabbe PFM, Postma MJ. Multivariate meta-analysis of preference-based quality of life values in coronary heart disease. *Submitted*.

Stevanović, Postma MJ, Le HH. Budget Impact Analysis of Current- and Increasing Market-share Scenarios for Point-of-Care Devices in Anticoagulation. *Submitted*.

Stevanović J, Dvortsin E, Kappelhoff B, Voorhaar M, Postma MJ. Dabigatran for the treatment and secondary prevention of venous thromboembolism. A cost-effectiveness analysis for the Netherlands. *Submitted*.

Conference presentations

Stevanović J, Pechlivanoglou P, Kampinga MA, Krabbe PFM, Postma MJ. Multivariate meta-analysis of preference-based quality of life values in coronary heart disease. Podium presentation at 36th Annual North American Meeting MDM.

Stevanovic J, Denee L, Koenders JM, Postma MJ. Incidence Description and Costs of Acute Heart Failure in the Netherlands. Podium presentation at 17th European ISPOR

congress, 2014, Amsterdam, the Netherlands. Abstract published: *Value in Health* 2014; 17(7): A328.

Stevanović J, Pechlivanoglou P, Postma MJ. Meta-analysis of preference-based quality of life values in heart failure. Poster presentation at 19th International ISPOR congress, 2014, Montreal, Canada. Abstract published: *Value in Health* 2014; 17(3): A197–A198.

Stevanović J, Pechlivanoglou P, Kampinga MA, Krabbe PFM, Postma MJ. Meta-Analysis of Quality of Life in Coronary Heart Disease. Poster presentation at 16th European ISPOR congress, 2013, Dublin, Ireland. Abstract published: *Value in Health* 2013; 16(7): A600.

Stevanović J, Pompen M, Le HH, Rozenbaum MH, Tieleman RG, Postma MJ. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. Poster presentation at 16th European ISPOR congress, 2013, Dublin, Ireland. Abstract published: *Value in Health* 2013; 16(7): A529.

Stevanovic J, Postma MJ, Pechlivanoglou P. Systematic Review on the Application of Cardiovascular Risk Prediction Models in Pharmacoeconomics, With a Focus on Primary Prevention. Poster presentation at 15th European ISPOR congress, 2013, Berlin, Germany. Abstract published: *Value in Health* 2012; 15(7): A467–A468.

Stevanović J, O'Prinsen AC, Postma MJ, Pechlivanoglou P. Economic Evaluation of Primary Prevention of Cardiovascular Diseases in Mild Hypertension: A Scenario Analysis for the Netherlands. Poster presentation at 14th European ISPOR congress, 2012, Madrid, Spain. Abstract published: *Value in Health* 2011; 14(7): A376.